Lifetime Genistein Intake May Improve Response to Tamoxifen

Share this content:
Lifetime Genistein Intake May Improve Response to Tamoxifen
Lifetime Genistein Intake May Improve Response to Tamoxifen

THURSDAY, Feb. 2, 2017 (HealthDay News) -- Lifetime intake of soy isoflavone genistein (GEN) improves the response of mammary tumors to tamoxifen (TAM) therapy in a rat model, according to an experimental study published online Feb. 1 in Clinical Cancer Research.

Xiyuan Zhang, Ph.D., from Georgetown University in Washington, D.C., and colleagues compared the effects of GEN intake mimicking Asian (lifetime) or Caucasian (adulthood) intake patterns. Female Sprague-Dawley rats were fed a diet supplemented with 0 (control) or 500 ppm GEN (lifetime GEN) from postnatal day 15. After induction of mammary tumors, a group of control rats was switched to the GEN diet (adult GEN). When the first tumor reached 1.4 cm in diameter, TAM was added to the diet and a subset of control rats started GEN intake (post-diagnosis GEN).

The researchers found that compared with post-diagnosis GEN, lifetime GEN intake reduced de novo resistance to TAM. Compared with the post-diagnosis GEN group, the risk of recurrence was lower in the lifetime and adult GEN groups. Compared with controls, post-diagnosis, and/or adult GEN groups, the lifetime GEN group had downregulation of unfolded protein response (UPR), autophagy-related genes, and genes linked to immunosuppression as well as upregulation of cytotoxic CD8a in tumors.

"GEN intake mimicking Asian consumption patterns improved response of mammary tumors to TAM therapy and this effect was linked to reduced activity of UPR and pro-survival autophagy signaling, and increased anti-tumor immunity," the authors write.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Bavencio for Merkel Cell Carcinoma

FDA Approves Bavencio for Merkel Cell Carcinoma

Drug targets the PD-1/PD-L1 pathway; first sanctioned treatment in the United States

Heterogeneous Association for Alcohol, CVD Presentation

Heterogeneous Association for Alcohol, CVD Presentation

Non-drinking linked to increased risks of unstable angina, MI, heart failure, ischemic stroke, PAD, AAA

Mobile App Cuts In-Person Visits After Breast Reconstruction

Mobile App Cuts In-Person Visits After Breast Reconstruction

Number of visits down, increase in e-mails to doctors for ambulatory patients undergoing breast recon

is free, fast, and customized just for you!

Already a member?

Sign In Now »